Due to the exclusive presence of residual adenocarcinoma of the primary lesion and a positive PD-L1-/CPS-Score of 6, we administered systemic chemotherapy with FOLFOX accompanied by immunotherapy with Nivolumab for three months, followed by maintenance therapy with Nivolumab monotherapy. The gene discussed is CD274; the disease is adenocarcinoma.